aclacinomycin has been researched along with azacitidine in 4 studies
Studies (aclacinomycin) | Trials (aclacinomycin) | Recent Studies (post-2010) (aclacinomycin) | Studies (azacitidine) | Trials (azacitidine) | Recent Studies (post-2010) (azacitidine) |
---|---|---|---|---|---|
168 | 8 | 21 | 7,474 | 479 | 3,782 |
Protein | Taxonomy | aclacinomycin (IC50) | azacitidine (IC50) |
---|---|---|---|
DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gahrton, G | 1 |
Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
1 review(s) available for aclacinomycin and azacitidine
Article | Year |
---|---|
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
1 trial(s) available for aclacinomycin and azacitidine
Article | Year |
---|---|
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
2 other study(ies) available for aclacinomycin and azacitidine
Article | Year |
---|---|
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |